Study on the initial treatment of Whipple's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN45658456

Enrollment

Registered

2004-07-21

Start date

1999-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Whipple's Disease Digestive System Whipple's disease

Interventions

Amended on 17/08/2007: Intravenous ceftriaxon versus intravenous meropenem/imipenem, followed by 12 months of oral co-trimoxazole. Enrolment for these two arms was completed in December 2003. A no

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Whipple-typical macrophages in the duodenal mucosa or elsewhere confirmed by the reference pathologist

Exclusion criteria

Exclusion criteria: 1. Current antimicrobial therapy for more than 1 month 2. Previous and unsuccessful antimicrobial therapy for Whipple's Disease 3. Recurrence of Whipple's Disease 4. Human Immunodeficiency Virus (HIV) infection, pregnancy, manifest tumor disease (except lymphoma)

Design outcomes

Primary

Measure	Time frame
Remission maintained for three years	—

Secondary

Measure	Time frame
Prospective collection of clinical, immunological, and pathological data concerning diagnosis and course of Whipple's disease.	—

Countries

Austria, France, Germany, Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 30, 2026